142 related articles for article (PubMed ID: 38719255)
41. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
42. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
43. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
44. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
45. CMV coinfection in treatment refractory immune checkpoint inhibitor colitis.
Harris KB; Funchain P; Baggott BB
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32434876
[TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.
Sisman G; Barbur E; Saka D; Erdamar Cetin S
Cancer Immunol Immunother; 2021 Aug; 70(8):2385-2388. PubMed ID: 33481043
[TBL] [Abstract][Full Text] [Related]
47. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
48. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
[TBL] [Abstract][Full Text] [Related]
49. A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function.
Sonwalkar SA; Holbrook IB; Phillips I; Kelly SM
Aliment Pharmacol Ther; 2003 Feb; 17(3):467-71. PubMed ID: 12562462
[TBL] [Abstract][Full Text] [Related]
50. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy.
Ishihara H; Watanabe T; Kumei S; Kume K; Yoshikawa I; Harada M
Clin J Gastroenterol; 2024 Feb; 17(1):46-51. PubMed ID: 38041760
[TBL] [Abstract][Full Text] [Related]
51. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
52. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.
Abu-Sbeih H; Wang Y
Inflamm Bowel Dis; 2020 Apr; 26(5):662-668. PubMed ID: 31560045
[TBL] [Abstract][Full Text] [Related]
53. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
[TBL] [Abstract][Full Text] [Related]
54. Unusual case of immune-related colitis.
Issa M; Milioglou I
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978598
[TBL] [Abstract][Full Text] [Related]
55. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Thomas M; Armenti ST; Ayres MB; Demirci H
JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
[TBL] [Abstract][Full Text] [Related]
56. Cascade of immunologic adverse events related to pembrolizumab treatment.
Dhenin A; Samartzi V; Lejeune S; Seront E
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
[TBL] [Abstract][Full Text] [Related]
57. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
58. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
59. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Tang L; Wang J; Lin N; Zhou Y; He W; Liu J; Ma X
Front Immunol; 2021; 12():800879. PubMed ID: 34992611
[TBL] [Abstract][Full Text] [Related]
60. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
